SPP1 and disease of the tendon: From the study, we believe that blocking the CD44 receptor on diseased tenocytes or knocking down the SPP1 gene in macrophages in the pathological environment may delay the occurrence and development of tendon HO, thus achieving a therapeutic effect on tendinopathy.